Elicio Therapeutics Secures $10M Financing for Operations

An update from Elicio Therapeutics ( (ELTX) ) is now available.

On June 3, 2025, Elicio Therapeutics entered into a $10 million senior secured promissory note agreement with GKCC, LLC, an entity controlled by a board member, to support its operations into the first quarter of 2026. The financing will help Elicio advance its AMP platform and ELI-002 program, targeting mKRAS-driven tumors, with the anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025 serving as a critical validation opportunity.

The most recent analyst rating on (ELTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.

Spark’s Take on ELTX Stock

According to Spark, TipRanks’ AI Analyst, ELTX is a Underperform.

Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.

To see Spark’s full report on ELTX stock, click here.

More about Elicio Therapeutics

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company leverages its proprietary Amphiphile (AMP) technology to enhance cancer-specific T cell responses, aiming to create effective off-the-shelf vaccines that offer benefits such as low cost and rapid availability.

Average Trading Volume: 40,044

Technical Sentiment Signal: Buy

Current Market Cap: $124M

Learn more about ELTX stock on TipRanks’ Stock Analysis page.